single faculty member

  • Dr.

    Jamal Mahajna
  • Senior Lecturer

  • Nutritional Sciences - B.Sc. Program
  • 054-6780089
  • jamalm@telhai.ac.il
    • Medicine
    • Molecular Biology
  • Graduated from the Medical school at the Hebrew University under the supervision of Prof. Amos Oppenheim specialized in molecular genetics and regulation of gene expression. I am an author of more than 40 publications, including refereed research papers, review papers, chapters in books and patents. After my graduation, I joined OSI pharmaceuticals (OSIP), NY, USA and become an integral part of the cancer program working with close collaboration with scientist from Pfizer, CT, USA. 

     Currently, I am the head of the department of cancer drug discovery program at Migal, Kiryat Shmona. My main interest is in overcoming cancer drug resistance, and in particular, in Ph+ leukemia.  To overcome drug resistance caused by point mutations within BCR/ABL gene, specially the "gatekeeper" T315I mutation, we explored modulators of the Myristoyl Binding Pocket (MBP) {Khamaisie et al., 2011; Najajreh et al., 2013} and combinations approaches utilizing Abl kinase inhibitors (AKIs) with allosteric inhibitors {Khateb et al., 2012; Mian et al., 2012}. Morepver, we also addressing residual disease, cell-adhesion mediated drug resistance, and disease progression of Ph+ leukemia which is independent of BCR/ABL mutations. Specifically, we are exploring the interaction between the Ph+ leukemic cells to the bone marrow microenvironment and studying the role of epithelial-mesenchymal transition (EMT) activators in mediating homing and adhesion to the bone marrow, which is regulated by factors such as CD44, CD184, and N-cadherin that contribute to residual disease, stimulate drug resistance, and accelerate disease progression in most hematopoietic malignancies. 

    In addition, we also interested in anti-cancer activity of natural products including herbs, medicinal plants and mushrooms. Our goal of using natural products or herbs is not to replace current cancer therapeutics but rather to augment their activity as adjuvants or to reduce side effects. In addition, utilizing natural products we will be able to identify novel chemical entities (NCEs) with desired activity and upon modifications and optimizing they might serve as novel cancer chemotherapeutics. 

  • I am a senior lecturer at the faculty of Science and biotechnology and currently I am the chairperson of the Nutritional sciences department at Tel-Hai College.

    Teaching at Telhai College
    1.    Biotechnology in Medical Sciences. Biotechnology Department
    2.    Laboratory in medical Sciences. Biotechnology Department
    3.    Nutrition and Cancer. Nutritional Sciences Department
    4.    Molecular Bases of cancer. MSC students, Biotechnology Department
    5.    Nutrition for Cancer Prevention. Nutritional Sciences Department
    6.    Molecular Nutrition. Nutritional Sciences Department 

  • Full CV download
  • F.    Active Participation in Conferences : Oral Presentation in Scientific Conferences (2005-present) 
    1.    October 2005- the 3rd Third International Medicinal Mushroom Conference "Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer" Port Townsend, WA USA.
    2.    March 2007-Frontiers of Science and Engineering 2007 Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer" Seville, Spain
    3.    September 2007-The 4th International Medicinal Mushroom Conference "Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer", Ljubljana, Slovenia 
    4.    November 2007-The World Science Forum "Targeting the Myristoyl Binding Pocket (MBP) in Bcr-Abl: A Rational Approach for Designing Therapeutics for CML" Budapest, Hungary
    5.    October 2008-13th World Congress on Advances in Oncology and 11thInternational Symposium on Molecular Medicine "Overcoming acquired resistance in Gleevec-refractory CML" Crete, Greece.
    6.    May 2009- Scientists and Scholars: Advancing Human Right "A regional collaboration Project for the Development of Novel CML therapy", Rabat, Morocco.
    7.    September 2009- The 5th International Medicinal Mushroom Conference " Modulation of iNOS Expression by Medicinal Mushrooms:  Anti-inflammatory and Anti-cancer Potentials", Nantong, China. 
    8.    October 10, 2010. Galilee Biomedical conference. Synthesis, Characterization and In Vitro Efficacy of novel Cisplatin (IV) Pro-drugs that Overcome Intrinsic Resistance of Cisplatin
    9.    Sep 25, 2011, The 6th International Medicinal Mushroom Conference, Zagreb, Croatia  "Biologically Active Substances from Culinary-Medicinal Mushroom Coprinus comatus as Modulators of Androgen Receptor Activity in Prostate Cancer Cell Lines"
    10.    Sep 25, 2011, The 6th International Medicinal Mushroom Conference, Zagreb, Croatia  " Oleic acid is the active component in the mushroom Daedalea gibbosa that inhibits Bcr-Abl kinase auto-phosphorylation activity"
    11.    Oct 6-8, 2011, 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine "Allosteric Inhibitors of Abl kinase as CML therapeutics". Rhodes Island, Greece
    12.    Oct 25, 2011 2nd Galilee Biomedical Conference, Kiryat Shmona "Allosteric Inhibitors of Abl kinase as CML therapeutics".
    13.    Sep 13, 2012; The annual meeting of Clinical Nutrition: Nutrition for Cancer starvation.
    14.    April 19, 2013; Snail overexpression in Ph-positive cells confers drug resistance to AKIs. Laboratory for Tumor Stem Cell Biology, Department of Hematology, J.W. Goethe University, Frankfurt, Germany.
    15.    May 27, 2013. Mushrooms Substances as Prostate Cancer Therapeutics. Israel Nutrition Week, preventive nutrition, Tel-Aviv. 
    16.    Sep 27, 2103. Snail overexpression confers resistance to Abl kinase inhibitors and collateral sensitivity to Gemcitabine in Ph-positive leukemic cancer cells. ECCO 17 - 38th ESMO- 32nd ESTRO European Cancer Congress, Amsterdam.

    17.    Aug 31 2015, MEDINICAL MUSHROOMS TO OVERCOME AQUIRED RESISTANE IN PH POSITIVE LEUKEMIA. The first International Conference on Natural Product for Cancer Prevention and Therapy. Istanbul, Turkey.

    18.    Oct 8, 2015, Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. 20th World Congress on Advances in Oncology and  18th International Symposium on Molecular Medicine, Athens, Greece 

    Posters presented in scientific conferences (2005-present) 
    1.    Zaidman BZ, Mahajna J, Wasser SP. Poster presented at the 4th Congress of the Federation of the Israel Societies for Experimental Biology, February 2005, Eilat, Israel. "Secondary metabolites from edible and medicinal mushrooms as molecular therapy for prostate cancer". 
    2.    Mahajna J., Zaidman BZ,  Wasser SP. Poster presented at the 3rd International Medicinal Mushroom Conference, October 2005, Port Townsend, Washington, USA. "Secondary metabolites from edible and medicinal mushrooms as molecular therapy for prostate cancer".
    3.    Roumyana D. Petrova, Nili Ruimi, Sherbel Sussan, Solomon P. Wasser, Eviatar Nevo, Abraham Z. Reznick, and Jamal Mahajna. Poster presented in the 4th International medicinal mushroom conference, Sep 2007, Ljubljana, Slovenia. "Inhibitory Effects of Marasmius oreades Extract Fractions on NF-kB Activation Pathway".
    4.    Nili Ruimi, Solomon Wasser and Jamal Mahajna. Poster presented in ISOFRR 2007. The 23th annual meeting of the Israeli Society for Oxygen and Free Radical Research, Dec 2008, Tel Aviv University, Israel.
    5.    Roumyana D. Petrova, Nili Ruimi, Sherbel Sussan, Solomon P. Wasser, Eviatar Nevo, Abraham Z. Reznick, and Jamal Mahajna. Poster presented in FISEB 2008, Eilat, Israel. "Inhibitory Effects of Marasmius oreades Fractions on NF-kB Activation Pathway".
    6.    Nili Ruimi,  Haithem Rwashdeh , Solomon Wasser and Jamal Mahajna Poster presented in ISOFRR 2008. The 24th annual meeting of the Israeli Society for Oxygen and Free Radical Research, Dec 2008, Wingate Institute, Israel. " Modulation of iNOS expression by medicinal mushrooms:  anti-inflammatory and anti-cancer potentials".
    7.    Gochman E, Mahajna J, Reznick A.Z. Poster presented in the Federation of European Biochemical Societies (FEBS) "Mechanisms, Consequences and Detection of Free Radical-Mediated Oxidative Protein Modification". April 2009, Antalya, Turkey. "The involvement of Reactive Nitrogen Species (RNS) in modulating transcription factor NF-κB and MAP kinases (MAPKs) pathways in colon cancer cells".
    8.    Riad Agbaria, A Konson , JA Mahajna , G Rimon. Poster presented in The 6th Annual Conference of the ISGCT. May 4, 2009. Ben Gurion University, Beer-Sheva, Israel. "effect of Herpes simplex virus thymidine kinase gene transduction on tumor cell biology
    9.    Dotan, N, Wasser, S and Mahajna, J " The 5th International Medicinal Mushroom Conference-Sep 2009, Nantong, China "Crude Extracts from the Culinary-medicinal Mushroom Coprinus comatus influence Androgen Receptor activity in Prostate Cancer cell line Mushroom".
    10.    Einat Gochman, Jamal Mahajna and Abraham Reznick in the 25th annual meeting of the Israeli Society for Oxygen and free Radical research" Dec 13, 2009. A dual mechanism of NF-kB activation by peroxynitrite through p38 MAP kinase dependent IKBa-phosphorylation, versus IKBa nitration in colon cancer cells.
    11.    Afsar Mian, Anna Metodieva, Yousef Najajreh, Hubert Serve1, Oliver Ottmann, Jamal Mahajna  and Martin Ruthardt , in the 52nd ASH Annual Meeting and Exposition, December 4-7, 2010. The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL
    12.    Hazem Khamaisi, Mamduh Khatteb, Linda Braik, Nida Eghreib, Amiram Goldblum, Martin Ruthardt, Yousef Najajreh, Jamal Mahajna , in the 6th FISEB, Feb 7-10,2011.Myristate analogs as BCR/ABL allosteric inhibitors for the treatment of Philadelphia positive leukemia
    13.    Einav Ratzon ,  Yousef Najajreh , Rami Salem,  Nili Ruimi,  Linda Braik  , Hazem Khamaisi,  Martin Ruthardt,  Jamal Mahajna, in the 6th FISEB, Feb 7-10, 2011. Synthesis, characterization and in vitro efficacy of novel Cisplatin-IV pro drugs overcoming intrinsic resistance to Cisplatin
    14.    Nili Ruimi ,Mamduh Khatteb, Yousef Najajreh, Martin Ruthardt, Jamal Mahajna, the 6th FISEB, Feb 7-10, 2011. Cooperation between GNF-2 and Abl kinase inhibitors (AKIs) in overcoming BCR/ABL T315I mutation
    15.    Nesly Dotan , Hazem Khamaisi, Solomon P. Wasser, Jamal Mahajna, in the 6th FISEB, Feb 7-10, 2011. Biologically active substances from culinary-medicinal mushroom Coprinus Comatus as modulators of androgen receptor activity in prostate cancer cell lines
    16.    Sani Kast, N., J. Mahajna,  Y. Najajreh,  M. Ruthardt and A. Goldblum (2011).  In the 9th International Conference on Chemical Structures, June 5-9 2011, Noordwijkerhout. The Netherlands. New Types Of Alloseric Inhibitors Against Bcr-Abl, Using Multiple Pharmacophore Models
    17.    Mamduh Khateb, Yousef Najajreh, Martin Ruthardt and Jamal Mahajna (2012). In Molecular Targeted Therapies: Mechanisms of Resistance, May 9-12 San Diego, Ca, USA.  Overcoming acquired resistance in Ph + leukemia.
    18.    Mahajna, J., Khamaisie, H., Ruimi, N., Agbarya, A., Eshel, E., Dally, N., Mian, AA, and Ruthardt, M. (2014). 794: Crizotinib is an allosteric ABL-inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia. July 5-8, Munich, Germany. EACR meeting.